Prophylaxis against Pneumocystis pneumonia in pediatric and adult patients undergoing solid organ or hematopoietic stem cells transplantation Profilaxis de neumonía por Pneumocystis jiroveci en niños y adultos sometidos a trasplante de órganos sólidos y d
Author
dc.contributor.author
Pilar Gambra, M.
Author
dc.contributor.author
Bidart, Teresa
Admission date
dc.date.accessioned
2019-03-15T16:03:29Z
Available date
dc.date.available
2019-03-15T16:03:29Z
Publication date
dc.date.issued
2012
Cita de ítem
dc.identifier.citation
Revista Chilena de Infectologia, Volumen 29, Issue SUPPL.1, 2018, Pages 19-22
Identifier
dc.identifier.issn
07161018
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/165842
Abstract
dc.description.abstract
Pneumocystis jiroveci is an important pathogen in patients undergoing SOT and HSCT. Universal prophylaxis is recommended for all adults and children with SOT and HSCT, considering that its use significantly reduces the occurrence and mortality associated with pneumonia by this agent. The drug of choice is cotrimoxazole (A1) three times a week, low-dose scheme, that has proved equally effective and better tolerated than the daily regimen and/or at high doses. Prophylaxis starts 7 to 14 days post transplant in SOT recipients and post-implant in HSCT, with an average duration of 6 months except in liver and lung transplant as in HSCT with significant degree of immunosuppression, that lasts for 1 year. Alternatives for prophylaxis are dapsone (B2), aerosolized pentamidine (B2) and atovaquone (C2).
Prophylaxis against Pneumocystis pneumonia in pediatric and adult patients undergoing solid organ or hematopoietic stem cells transplantation Profilaxis de neumonía por Pneumocystis jiroveci en niños y adultos sometidos a trasplante de órganos sólidos y d